Treatment of chemotherapy-induced nausea

Community Oncology

Volumn 9, Issue 1, 2012, Pages 20-26

  Navari, Rudolph M ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; AZASETRON; DEXAMETHASONE; DOLASETRON MESILATE; DRONABINOL; GABAPENTIN; GRANISETRON; METOCLOPRAMIDE; NABILONE; OLANZAPINE; ONDANSETRON; PALONOSETRON; PLANT MEDICINAL PRODUCT; PROCHLORPERAZINE; RAMOSETRON; RANITIDINE; TROPISETRON;

ACNE; ACUTE DISEASE; AGITATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; EPIGASTRIC DISCOMFORT; GINGER; HUMAN; HYPERGLYCEMIA; INCREASED APPETITE; INDIGESTION; INSOMNIA; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 84856628659     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmonc.2011.11.001     Document Type: Review

References (51)

1. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed Nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24(27):4472-4478.
2. Navari RM. Pharmacological management of chemotherapyinduced nausea and vomiting: focus on recent developments. Drugs. 2009;69(5):515-533.
3. Navari RM. Palonosetron for the prevention of chemotherapyinduced nausea and vomiting in patients with cancer. Future Oncol. 2010;6(7):1073-1084.
4. Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs. 2009;69(13):1853-1858.
5. Sankhala KK, Pandya DM, Sarantopoulos J, Soefje SA, Giles FJ, Chawla SP. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol. 2009;5(12): 1607-1614.
6. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer. 2005; 13(7):529-534.
7. Navari RM, Einhorn LH, Loehrer PJ Sr, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer. 2007; 15(11):1285-1291.
8. Tan L, Liu J, Liu X, et al. Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 2009;28(1):131.
9. Stern RM, Koch KL, Andrews PLR. Nausea: Mechanisms and Management. New York (NY): Oxford University Press; 2011.
10. Simpson K, Spencer CM, McClellan KJ. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2000;59(6):1297-1315.
11. Kimura E, Niimi S, Watanabe A, Akiyama M, Tanaka T. Study on the clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho. 1996;23(4):477-481.
12. Taguchi T, Tsukamoto F, Watanabe T, et al. Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho. 1999;26(8):1163-1170.
13. WHO Drug Information, 40, No. 3, 2006.
14. U.S. Food and Drug Information. FDA Drug Safety Communication: Abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm. Accessed December 27, 2010.
15. Roila F, Warr D, Clark-Snow RA, et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005;13(2):104-108.
16. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6):1289-1294.
17. Hickok JT, Roscoe JA, Morrow GR, et al. 5-hydroxytryptamine-3 receptor antagonists versus perchlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol. 2005;6(10):765-772.
18. Navari RM. Pathogenesis-based treatment of chemotherapyinduced nausea and vomiting-two new agents. J Support Oncol. 2003; 1(2):89-103.
19. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for the prevention of nausea and vomiting during chemotherapy: a double-blind, doubledummy, randomised, comparative phase III trial. Lancet Oncol. 2009; 10(2):115-124.
20. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822-2830.
21. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol. 2004;15(2):330-337.
22. Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2010;626(2-3):193-199.
23. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17(9):1441-1449.
24. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98(11):2473-2482.
25. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a doubleblind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14(10):1570-1577.
26. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24(18):2932-2947.
27. NCCN National Comprehensive Cancer Network. Antiemesis: Clinical Practice Guidelines in Oncology (2010) v 1. www.nccn.org.
28. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy- induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):232-243.
29. Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer. 2006;14(4):354-360.
30. Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy- induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 2005;41(9): 1278-1285.
31. Grote T, Hajdenberg J, Cartnell A, et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol. 2006;4(8):403-408.
32. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 2006; 94(7):1011-1015.
33. Celio L, Frustaci S, Denaro A, et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer. 2011;19(8): 1217-1225.
34. Aapro M, Fabi A, Nolè F, et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol. 2010;21(15):1083-1088.
35. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87-96.
36. Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol. 2001; 430(2-3):341-349.
37. Allison DB, Casey DE. Antipsychotic-associated weight gain: a review of the literature. J Clin Psychiatry. 2001;62(suppl 7):22-31.
38. Hale AS. Olanzapine. Br J Hosp Med. 1997;58(9):443-445.
39. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999;40(5):438-443.
40. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the control of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9(5):188-195.
41. Irving G, Jensen M, Cramer M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain. 2009;25(3):185-192.
42. Guttuso T Jr, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet. 2003; 361(9370):1703-1705.
43. Cruz FM, de Iracema Gomes Cubero D, Taranto P, et al. Gabapentin for the prevention of chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer. 2011 Apr 5 [Epub ahead of print].
44. Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA. Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol. 2003;285(3):G566-G576.
45. Darmani NA. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol Biochem Behav. 2001;69(1-2):239-249.
46. Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23(3):533-543.
47. Davis MP. Oral nabilone capsules in the treatment of chemotherapy- induced nausea and vomiting and pain. Expert Opin Investig Drugs. 2008;17(1):85-95.
48. Mills S, Bone K. Principles and Practice of Phytotherapy. Oxford, England: Churchill Livingstone; 2000.
49. Pillai AK, Sharma KK, Gupta YK, Bakhshi S. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer. 2011;56(2):234-238.
50. Zick SM, Ruffin MT, Lee J, et al. Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer. 2009;17(5):563-572.
51. Ryan JL, Heckler C, Dakhil SR, et al. Ginger for chemotherapyrelated nausea in cancer patients: a URCC CCOP randomized, doubleblind, placebo-controlled clinical trial of 644 cancer patients. J Clin Oncol. 2009;27[suppl 5]:9511.